In addition, type II diabetes is related to worsening of functional outcome.[21] However, recent report of glycated albumin level could be a potential biomarker of the effect of antiplatelet therapy in patients with minor stroke or TIA[17,22]. This evidence concerns the gene ALB and type 2 diabetes mellitus.